New Research Shows Silencing Role for Non-slicer Argonaute Proteins | GenomeWeb

NEW YORK (GenomeWeb) – A Massachusetts Institute of Technology-led research team this month reported new data suggesting that an siRNA targeting a messenger RNA's 3' untranslated region (UTR), rather than its coding sequence (CDS), can harness the activity of multiple Argonaute proteins to better suppress its target.

As such, RNAi-based therapeutics might benefit from targeting 3' UTRs in order to engage Ago proteins that lack any slicing activity into the target knockdown process, the scientists wrote in their study.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.